TY - JOUR
T1 - Versatile Methodology to Encapsulate Gold Nanoparticles in PLGA Nanoparticles Obtained by Nano-Emulsion Templating
AU - Fornaguera, Cristina
AU - Feiner-Gracia, Natàlia
AU - Dols-Perez, Aurora
AU - García-Celma, Maria José
AU - Solans, Conxita
N1 - Funding Information:
Financial support from MINECO (grants CTQ2014-52687-C3-1-P and CTQ2016-80645-R); Generalitat de Catalunya (grant 2014-SGR-1655), and CIBER-BBN are acknowledged. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. Cristina Fornaguera is grateful to AGAUR for their Predoctoral Fellowship (grant FI-DGR 2012). Natàlia Feiner is grateful to CIBER-BBN for their Research Initiation Fellowship.
Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Purpose: Gold nanoparticles have been proved useful for many biomedical applications, specifically, for their use as advanced imaging systems. However, they usually present problems related with stability and toxicity. Methods: In the present work, gold-nanoparticles have been encapsulated in polymeric nanoparticles using a novel methodology based on nano-emulsion templating. Firstly, gold nanoparticles have been transferred from water to ethyl acetate, a solvent classified as class III by the NIH guidelines (low toxic potential). Next, the formation of nano-emulsions loaded with gold nanoparticles has been performed using a low-energy, the phase inversion composition (PIC) emulsification method, followed by solvent evaporation giving rise to polymeric nanoparticles. Results: Using this methodology, high concentrations of gold nanoparticles (>100 pM) have been encapsulated. Increasing gold nanoparticle concentration, nano-emulsion and nanoparticle sizes increase, resulting in a decrease on the stability. It is noteworthy that the designed nanoparticles did not produce cytotoxicity neither hemolysis at the required concentration. Conclusions: Therefore, it can be concluded that a novel and very versatile methodology has been developed for the production of polymeric nanoparticles loaded with gold nanoparticles. [Figure not available: see fulltext.]
AB - Purpose: Gold nanoparticles have been proved useful for many biomedical applications, specifically, for their use as advanced imaging systems. However, they usually present problems related with stability and toxicity. Methods: In the present work, gold-nanoparticles have been encapsulated in polymeric nanoparticles using a novel methodology based on nano-emulsion templating. Firstly, gold nanoparticles have been transferred from water to ethyl acetate, a solvent classified as class III by the NIH guidelines (low toxic potential). Next, the formation of nano-emulsions loaded with gold nanoparticles has been performed using a low-energy, the phase inversion composition (PIC) emulsification method, followed by solvent evaporation giving rise to polymeric nanoparticles. Results: Using this methodology, high concentrations of gold nanoparticles (>100 pM) have been encapsulated. Increasing gold nanoparticle concentration, nano-emulsion and nanoparticle sizes increase, resulting in a decrease on the stability. It is noteworthy that the designed nanoparticles did not produce cytotoxicity neither hemolysis at the required concentration. Conclusions: Therefore, it can be concluded that a novel and very versatile methodology has been developed for the production of polymeric nanoparticles loaded with gold nanoparticles. [Figure not available: see fulltext.]
KW - AuNP-loaded polymeric nanoparticles
KW - nano-emulsion templating
KW - novel imaging systems
KW - phase inversion composition (PIC) emulsification method)
KW - polymeric nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85012929589&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000399164800016&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1007/s11095-017-2119-1
DO - 10.1007/s11095-017-2119-1
M3 - Article
C2 - 28197757
AN - SCOPUS:85012929589
SN - 0724-8741
VL - 34
SP - 1093
EP - 1103
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 5
ER -